Background: Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III trials excluded patients with nccRCC, which constitute about 30% of metastatic RCC cases.
Aim: To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.
Methods: The present study is a multicenter retrospective observational analysis aiming to assess the activity, efficacy, and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.
Results: Overall, 48 patients were included. At the median follow-up of 40.6 mo, the objective response rate was 27.1%, the disease control rate was 83.3%, and the median progression-free survival and overall survival were 12.3 (95% confidence interval [CI]: 3.6-20.9) and 27.7 (95%CI: 18.2-37.1) mo, respectively. Grade 3 adverse events occurred in 20% of patients, and no grade 4 or 5 toxicities were found.
Conclusion: Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology.
Keywords: Kidney cancer; Non-clear cell; Pazopanib; Renal-cell carcinoma; Tyrosine kinase inhibitors; Variant histology.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.